The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2, 2011New Roles for the Parkinson's Disease Kinase LRRK2 in Cytoskeletal Dynamics
Objective/Rationale:
LRRK2, a key protein in Parkinson’s disease, may have a role in regulating the cytoskeleton. The cytoskeleton in nerve cells (neurons) is crucial for the growth of neuronal... -
Rapid Response Innovation Awards, 2011Informing Clinical Decision Making in the Pre-motor Period of Parkinson Disease
Objective/Rationale:
Currently, the diagnosis of Parkinson disease (PD) relies on recognition of impaired movement, which occurs decades after neurodegeneration begins. By looking at changes in sleep... -
Therapeutics Development Initiative, 2011Xenon inhalation to reduce L-Dopa-induced dyskinesia
Objective/Rationale:
Levodopa is the most effective drug to treat symptoms of Parkinson’s disease, however long-term use leads to disabling levodopa-induced dyskinesia (LID) in the vast majority of... -
Therapeutics Development Initiative, 2011Pharmacokinetics and Cognitive Side Effects of the Antidyskinetic Drug Fenobam in MPTP-treated Pre-clinical Models
Promising Outcomes of Original Grant:
The goal of our original project was to determine if a prodrug of acamprosate could inhibit levodopa-induced dyskinesias (LIDs) in a pre-clinical model. During... -
LRRK2, 2011The Role of LRRK2 in Regulating a Calcium-Dependent Pathway Involving Lysosomal Stores and NAADP
Objective/Rationale:
Our preliminary evidence indicates that LRRK2 may regulate acidic calcium stores, with downstream effects on autophagy as well as a variety of other calcium dependent cellular... -
Target Validation, 2011Tau Oligomers as a Potential Target for Treatment of Parkinson's Disease
Objective/Rationale:
Tau pathology is a prominent feature of synucleinopathies, such as Parkinson disease (PD) and dementia with Lewy Bodies (DLB). An emerging view in neurodegeneration is that...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.